Madrigal keeps buying its way into combination MASH therapy

Fierce Biotech interviews Madrigal’s CEO on a year of licensing deals meant to pair with Rezdiffra in fatty liver disease.

Fierce Biotech published an interview with Madrigal Pharmaceuticals' chief executive on the strategy behind the company's 2026 acquisition run, in which it has licensed a range of drugs it hopes will work alongside Rezdiffra, its approved treatment for metabolic dysfunction-associated steatohepatitis.

The reasoning is that MASH will likely be treated with combinations rather than any single agent, and that assembling those combinations early is how a company holds a category while it is still forming. For patients, more combinable options is genuinely better than one drug. Concentrating them inside a single company is also how the price of the eventual combination gets set.

This is an interview about strategy, not a deal announcement or a trial readout. The source page blocked automated retrieval, so this brief carries no deal terms or figures — that detail sits with the publisher.

Source: Fierce Biotech